Additional file 1 of Radiographic involvement of cervical facet joints in ankylosing spondylitis: a longitudinal analysis in correlation with vertebral body lesions

Supplementary Material

Additional file 4 of WNT16 elevation induced cell senescence of osteoblasts in ankylosing spondylitis

Additional file 4: Supplementary Figure 4. WNT16 treatment inhibited ALP activity in AS-osteoprogenitors. AS-osteoprogenitors were plated in 96 wells plate and treated with 0, 25, or 50 ng/ml WNT16, and then analyzed as indicated by (A) WST assay for cell proliferation. (B) ALP and COL staining, and (C) ALP activity. Data are presented as the mean ± SD (n=3). *p<0.05

Additional file 3 of WNT16 elevation induced cell senescence of osteoblasts in ankylosing spondylitis

Additional file 3: Supplementary Figure 3. Analysis of WNT16 level in collected sera. The human WNT16 levels were measures in the collected sera (HC, n=3; AS, n=36) using ELISA. N.S., not significant

Additional file 1 of WNT16 elevation induced cell senescence of osteoblasts in ankylosing spondylitis

Additional file 1: Supplementary Figure 1. The overall image of a well for 96 well plates and its enlarged changes by Nikon microscopy

Additional file 2 of WNT16 elevation induced cell senescence of osteoblasts in ankylosing spondylitis

Additional file 2: Supplementary Figure 2. The result of siRNA efficiency test. (A) Total four human osteoblasts cell lines (MG63, FOB, SaOS2, U2OS) were extracted total RNA and analyzed by RT-PCR to test WNT16 level. (B) FOB cell were transfected with five siRNA oligo against human WNT16 and analyzed by RT-PCR for siRNA efficiency